Advances in gastrointestinal pharmacotherapy

Clinical Gastroenterology and Hepatology

Volumn 3, Issue 12, 2005, Pages 1167-1179

  Metz, David C ^a   Vakil, Nimish ^b,c   Keeffe, Emmet B ^d   Lichtenstein, Gary R ^a,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MARQUETTE UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Division of Gastroenterology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; ABT 874; ADALIMUMAB; ALICAFORSEN; ALPHA METHYLHISTAMINE; ANTACID AGENT; AZD 0865; BENATOPRAZOLE; BENZIMIDAZOLE DERIVATIVE; CC 1088; CERTOLIZUMAB PEGOL; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CIMETIDINE; COLCHICINE; CS 526; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; ESOMEPRAZOLE; GASTRIN ANTAGONIST; GW 3333; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; ILAPRAZOLE; INFLIXIMAB; INTERFERON; ITRIGLUMIDE; MLN 02; OMEPRAZOLE; PANTOPRAZOLE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; POTASSIUM DERIVATIVE; PROTON PUMP INHIBITOR; REVAPRAZAN; RIBAVIRIN; SEMAPIMOD; SORAPRAZAN; THIOPERAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VISILIZUMAB; Z 360;

CAPSULE ENDOSCOPE; CELL ACTIVITY; CELL ADHESION; CELL MIGRATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DELAYED HYPERSENSITIVITY; DEMYELINATION; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG RESPONSE; DRY SKIN; ENTERIC COATED TABLET; ENTERITIS; ERADICATION THERAPY; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT FUNCTION; HEALTH CARE COST; HELPER CELL; HEPATITIS C; HUMAN; HYPERSENSITIVITY REACTION; LEUKOCYTE; LIVER TOXICITY; LONG TERM CARE; LUPUS VULGARIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MEDICAL SOCIETY; META ANALYSIS; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; POLARIZATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK FACTOR; SIDE EFFECT; STANDARDIZATION; STOMACH ACID; SUSPENSION; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; VIROLOGY;

CHICAGO; CONGRESSES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS;

EID: 29144527596     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(05)00895-5     Document Type: Review

References (102)

1. G.N. Tytgat Shortcomings of the first-generation proton pump inhibitors Eur J Gastroenterol Hepatol 13 Suppl 1 2001 S29 S33
2. J.G. Hatlebakk, P.O. Katz, B. Kuo Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily Aliment Pharmacol Ther 12 1998 1235 1240
3. P.O. Katz, J.G. Hatlebakk, D.O. Castell Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole Aliment Pharmacol Ther 14 2000 709 714
4. T. Andersson Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole Clin Pharmacokinet 31 1996 9 28
5. + ATPase Annu Rev Pharmacol Toxicol 35 1995 277 305
6. E.J. Kim, R.K. Lee, S.M. Lee General pharmacology of IY-81149, a new proton pump inhibitor Arzneimittelforschung 51 2001 51 59
7. Tenatoprazole. Benatoprazole, TU 199 Anonymous Drugs R D 3 2002 276 277
8. F. Domalga, H. Ficheux Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male Caucasian volunteers (abstr) Gastroenterology 124 2003 S1608
9. J.P. Galmiche, S. Bruley Des Varannes, P. Ducrotté Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life effects on intragastric pH and comparison with esomeprazole in healthy volunteers Aliment Pharmacol Ther 19 2004 655 662
10. J.P. Galmiche, S. Sacher-Huvelin, S. Bruley des Varannes A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers Aliment Pharmacol Ther 21 2005 575 582
11. D. Castell, R. Bagin, B. Goldlust Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease Aliment Pharmacol Ther 21 2005 1467 1474
12. S.A. Conrad, A. Gabrielli, B. Margolis Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients Crit Care Med 33 2005 760 765
13. Available at: http://www.cnpp.usda.gov/FENR/V11N4/fenrv11n4p49.PDF. Accessed: July 23, 2005.
14. Available at: www.orexo.com. Accessed: July 23, 2005.
15. W. Beil, I. Hackbarth, K.F. Sewing Mechanism of gastric antisecretory effect of SCH 28080 Br J Pharmacol 88 1986 19 23
16. +)-ATPase as both potential therapeutic agents and probes of pump function Biochem Soc Trans 20 1992 566 572
17. W. Wurst, M. Hartmann Current status of acid pump antagonists (reversible PPIs) Yale J Biol Med 69 1996 233 243
18. G. Sachs, J. Moo Shin, O. Vagin Current trends in the treatment of upper gastrointestinal disease Best Pract Res Clin Gastroenterol 16 2002 835 849
19. K.S. Han, Y.G. Kim, J.K. Yoo Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs hepatic first-pass effect in rats Biopharm Drug Dispos 19 1998 493 500
20. K.S. Yu, K.S. Bae, J.H. Shon Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers J Clin Pharmacol 44 2004 73 82
21. Available at: http://www.altana.com/files/publikationen/finanzen/ praesentationen/20031009_sal-oppenheim_69.pdf. Accessed: July 23, 2005.
22. C. Nilsson, E. Albrektson, H. Rydholm Tolerability, pharmacokinetics and effects on gastric acid secretion after single oral doses of the potassium-competitive acid blocker ASD0865 in healthy male subjects Gastroenterology 138 2005 A-528
23. G. Coruzzi, E. Poli, G. Morini The histamine H3 receptor T.S. Gaginella A. Guglietta Molecular targets for drug development GI diseases 2000 Humana Press Totowa, NJ 239 267
24. G. Soldani, M. Garbarg, L. Intorre Modulation of pentagastrin-induced histamine release by histamine H3 receptors in the dog Scand J Gastroenterol 31 1996 631 638
25. F. Lehmann, P. Hildebrand, C. Beglinger New molecular targets for treatment of peptic ulcer disease Drugs 63 2003 1785 1797
26. Available at: http://www.rotta.com/pages/canali/r&d/profili/2945.asp. Accessed: July 23, 2005.
27. A.M. Smith, T. Morris, T. Justin Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model Aliment Pharmacol Ther 15 2001 1981 1988
28. T. Justin, S. Watson, D. Michaeli Gastric acid suppression using anti-gastrin 17 antibodies produced by a gastrin immunogen, Gastrimmune, in an in vivo pig model Gastroenterology 108 1995 A125
29. M.J. Alter, D. Kruszon-Moran, O.V. Nainan The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
30. A. Zaman, M.B. Fennerty, E.B. Keeffe Systematic review peginterferon vs. standard interferon in the treatment of chronic hepatitis C Aliment Pharmacol Ther 18 2003 661 670
31. M.P. Manns, J.G. McHutchinson, S.C. Gordon Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomized trial Lancet 358 2001 958 965
32. M.W. Fried, M.L. Shiffman, K.R. Reddy Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C virus infection N Eng J Med 347 2002 975 982
33. S.J. Hadziyannis, H. Sette Jr, T.R. Morgan Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
34. M.L. Shiffman Retreatment of patients with chronic hepatitis C Hepatology 36 Suppl 1 2002 S128 S134
35. S. Zeuzem Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C who responds less well? Ann Intern Med 140 2004 370 381
36. S.J. Cheng, P.A. Bonis, J. Lau Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy a meta-analysis of controlled and uncontrolled trials Hepatology 33 2001 231 240
37. K.J. Cummings, S.M. Lee, E.S. Wen Interferon and ribavirin vs. interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon JAMA 285 2001 193 199
38. R. San Miguel, F. Guillen, J.M. Cabases Combination therapy with interferon alfa-2a/b and ribavirin in patients with chronic hepatitis C previously non-responsive to interferon Aliment Pharmacol Ther 16 2002 1611 1621
39. M.L. Shiffman, A.M. Di Bisceglie, K.L. Lindsay Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023
40. I.M. Jacobsen, F. Ahmed, M.W. Russo Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results (abstr) Gastroenterology 124 Suppl 1 2003 A-714
41. T. Poynard, E. Schiff, R. Terg Sustained virologic response (SVR) in the EPIC3 Trial week twelve virology predicts SVR in previous interferon/ribavirin treatment failures receiving Peg-Intron/Rebetol (PR) weight based dosing (WBD) (abstr) J Hepatol 42 Suppl 2 2005 A96
42. S. Kaiser, H. Hass, M. Gregor Successful retreatment of peginterferon nonresponders with chronic hepatitis C with high dose consensus interferon induction therapy (abstr) Gastroenterology 124 Suppl 1 2003 A700
43. C. Leevy II, C. Chamers, L. Blatt Comparison of African American and non-African American patient end of treatment response for PEGIFN alpha-2a and weight based ribavirin nonresponders retreated with IFN alfacon-1 and weight based ribavirin (abstr) Hepatology 40 Suppl 1 2004 240A
44. M. Diago, J. Crespo, A. Oliveira Peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin final results of the Spanish high dose induction pilot trial (abstr) Hepatology 40 Suppl 1 2004 389A
45. J.M. Sanchez-Tapias, M. Diago, P. Escartin Longer treatment duration with peginterferon alfa-2a (40kd) (Pegasys) and ribavirin (Copegus) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy final results of the randomized, multicenter Teravic-4 study (abstr) Hepatology 40 Suppl 1 2004 218A
46. M.L. Shiffman, C.M. Hofmann, M.J. Contos A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders Gastroenterology 117 1999 1164 1172
47. M.L. Shiffman, C.M. Hofmann, E.B. Thompson Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C Hepatology 26 1997 780 785
48. W.M. Lee, J.L. Dienstag, K.L. Lindsay Evolution of the halt-c trial pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders Control Clin Trials 25 2004 472 492
49. N. Afdhal, B. Freilich, R. Levine Colchicine versus Peg-Intron long term (CoPilot) trial interim analysis of clinical outcomes at year 2 (abstr) Hepatology 40 Suppl 1 2004 239A
50. W.J. Sandborn New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease Rev Gastroenterol Disord 5 2005 10 18
51. R. Srinivasan, G.R. Lichtenstein Recent developments in the pharmacological treatment of Crohn's disease Expert Opin Investig Drugs 13 2004 373 391
52. P. Rutgeerts, B.G. Feagan, A. Olson A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis Act I trial (abstr) Gastroenterology 127 2005 A-105
53. W.J. Sandborn, D. Rachmilewitz, S.B. Hanauer Infliximab induction and maintenance therapy for ulcerative colitis the Act 2 trial (abstr) Gastroenterology 127 2005 A-104
54. S. Mascheretti, S. Schreiber The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease Pharmacogenomics 5 2004 479 486
55. J.R. Bebb, B.B. Scott How effective are the usual treatments for Crohn's disease? Aliment Pharmacol Ther 20 2004 151 159
56. W.J. Sandborn, S. Hanauer, E.V. Loftus Jr An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease Am J Gastroenterol 99 2004 1984 1989
57. A. Youdim, E.A. Vasiliauskas, S.R. Targan A pilot study of adalimumab in infliximab-allergic patients Inflamm Bowel Dis 10 2004 333 338
58. S. Hanauer, M. Lukáš, D. MacIntosh A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease (abstr) Gastroenterology 127 2004 332
59. T.A. Winter, J. Wright, S. Ghosh Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease an exploratory study Aliment Pharmacol Ther 20 2004 1337 1346
60. S. Schreiber, P. Rutgeerts, R. Fedorak A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease Gastroenterology 129 2005 807 818
61. W.J. Sandborn, S.B. Hanauer, S. Katz Etanercept for active Crohn's disease a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
62. P. Rutgeerts, L. Lemmens, G. Van Assche Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor) results of a randomized, open-label, pilot study Aliment Pharmacol Ther 17 2003 185 192
63. D. Hommes, B. van den Blink, T. Plasse Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease Gastroenterology 122 2002 7 14
64. S. Murthy, A. Flanigan, D. Coppola RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis Inflamm Res 51 2002 522 531
65. S. Travis, L.M. Yap, C. Hawkey RDP Investigator Study Group RDP58 is a novel and potentially effective oral therapy for ulcerative colitis Inflamm Bowel Dis 11 2005 713 719
66. J. Bauditz, S. Wedel, H. Lochs Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease Gut 50 2002 196 200
67. C. Bariol, A.P. Meagher, C.R. Vickers Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease J Gastroenterol Hepatol 17 2002 135 139
68. J.N. Gordon, P.M. Goggin Thalidomide and its derivatives emerging from the wilderness Postgrad Med J 79 2003 127 132
69. J.G. Conway, R.C. Andrews, B. Beaudet Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases J Pharmacol Exp Ther 298 2001 900 908
70. W.-C. Lim, S.B. Hanauer Emerging biologic therapies in inflammatory bowel disease Rev Gastroenterol Disord 4 2004 66 85
71. B. Vainer, S. Berliner, O.H. Nielsen Spontaneous aggregation of leukocytes in active ulcerative colitis might be ICAM-1 dependent Inflamm Res 53 2004 458 461
72. S. Ghosh, E. Goldin, F.H. Gordon Natalizumab Pan-European Study Group Natalizumab for active Crohn's disease N Engl J Med 348 2003 24 32
73. W.J. Sandborn How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease Rev Gastroenterol Disord 4 Suppl 3 2004 S25 S33
74. W. Sandborn, J.-F. Colombel, R. Enns A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2) Gastroenterology 127 2004 332
75. G. Van Assche, M. Van Ranst, R. Sciot Brief report progressive multifocal leukoencephalopathy after Natalizumab therapy for Crohn's disease N Engl J Med 353 2005 362 368
76. B.K. Kleinschmidt-DeMasters, K.L. Tyler Brief report progressive multifocal leukoencephalopathy complicating Natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 353 2005 369 374
77. A. Langer-Gould, S.W. Atlas, A.J. Green Brief report progressive multifocal leukoencephalopathy in a patient treated with Natalizumab N Engl J Med 353 2005 375 381
78. J.R. Berger, I.J. Koralnik Progressive multifocal leukoencephalopathy and Natalizumab - unforseen consequences N Engl J Med 353 2005 414 416
79. B.G. Feagan, G.R. Greenberg, G. Wild Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin N Engl J Med 352 2005 2499 2507
80. S.J. van Deventer, M. Volfova, R. Flisiak A phase 2 dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis (abstr) Gastroenterology 128 2005 A-74
81. B.R. Yacyshyn, M.B. Bowen-Yacyshyn, L. Jewell A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease Gastroenterology 114 1998 1133 1142
82. B.R. Yacyshyn, W.Y. Chey, J. Goff Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease Gut 51 2002 30 36
83. B.R. Yacyshyn, C. Barish, J. Goff Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease Aliment Pharmacol Ther 16 2002 1761 1770
84. S. Schreiber, S. Nikolaus, H. Malchow Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease Gastroenterology 120 2001 1339 1346
85. S.J. van Deventer, J.A. Tami, M.K. Wedel A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis Gut 53 2004 1646 1651
86. P. Miner, T. Nichols, H. Schwartz A phase 2 trial to assess the safety and efficacy of two dose formulations of Alicaforsen enema compared with 4g mesalamine enema for acute ulcerative colitis Gastroenterology 127 2005 A-74
87. T.T. Macdonald, G. Monteleone Immunity, inflammation, and allergy in the gut Science 307 2005 1920 1925
88. W.J. Sandborn, S.R. Targan Biologic therapy of inflammatory bowel disease Gastroenterology 122 2002 1592 1608
89. P.J. Mannon, I.J. Fuss, L. Mayer Anti-IL-12 Crohn's Disease Study Group Anti-interleukin-12 antibody for active Crohn's disease N Engl J Med 351 2004 2069 2079
90. D. Hommes, T. Mikhajlova, S. Stoinov Fontolizumab (HuZAF), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's disease (abstr) Gastroenterology 127 2004 332
91. W.J.S. de Villiers, S. Katz, B.A. Salzberg Chronic dosing of Fontolizumab (HuZAF™), a humanized anti-IFN-gamma antibody, in patients with moderate to severe Crohn's disease (CD) (abstr) Gastroenterology 127 2005 A-111
92. B. Siegmund, G. Fantuzzi, F. Rieder Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production Am J Physiol 281 2001 R1264 R1273
93. T. Kanai, M. Watanabe, A. Okazawa Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease Gastroenterology 121 2001 875 888
94. G. Van Assche, I. Dalle, M. Noman A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis Am J Gastroenterol 98 2003 369 376
95. T.J. Creed, M.R. Norman, C.S. Probert Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis Aliment Pharmacol Ther 18 2003 65 75
96. C. Gasche, W. Reinisch, H. Vogelsang Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease Dig Dis Sci 40 1995 800 804
97. B. Davidsen, P. Munkholm, P. Schlichting Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease Aliment Pharmacol Ther 9 1995 75 79
98. H.P. Wirth, G. Zala, C. Meyenberger [Alpha-interferon therapy in Crohn's disease initial clinical results] Schweiz Med Wochenschr 123 1993 1384 1388
99. S. Nikolaus, P. Rutgeerts, R. Fedorak Interferon beta-1a in ulcerative colitis a placebo controlled, randomised, dose escalating study Gut 52 2003 1286 1290
100. E. Musch, T. Andus, M. Malek Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis - an open long-term pilot trial Aliment Pharmacol Ther 16 2002 1233 1239
101. P.A. Carpenter, S. Pavlovic, J.Y. Tso Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells J Immunol 165 2000 6205 6213
102. S.R. Targan, B. Salzberg, L. Mayer A phase I-II study multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with IV steroids (IVSR-UC) (abstr) Gastroenterology 127 2005 A-75